ADC Therapeutics

Confronting cancer with the full potential of our science

ADC Therapeutics is a leading, commercial-stage global pioneer in the field of antibody drug conjugates (ADCs).

Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors.

Our senior leaders are industry veterans with experience in both large pharmaceutical companies and biotechnology startups and our highly skilled global workforce is committed to transforming the lives of patients with cancer.

Our Vision

We strive to be a leading antibody drug conjugate company that transforms the lives of those impacted by cancer

Our Values

Integrity - ethical and authentic in our approach
Creativity - innovate with an entrepreneurial spirit
Accountability - ownership to drive results
Collaboration - partner for better outcomes
Urgency - act decisively and proactively

Our Leadership
and the Board of Directors

Partnering

At ADC Therapeutics, we are on a mission to confront cancer with the full potential of our science to bring unique, targeted therapies and hope to patients and their families. To help support this mission, we actively seek innovative collaborations and strategic business development opportunities.

To start the conversation about partnering with ADC Therapeutics, please contact us at [email protected].

Charitable Contributions & Sponsorships

Charitable Contributions
ADC Therapeutics’ interactive portal accepts unsolicited requests for charitable contributions/donations. The Company will evaluate funding requests monthly for events/activities of registered 501(c)3 tax-exempt organizations engaged in a healthcare-related charitable purpose aligned with ADC Therapeutics’ mission and vision. Requests will also be reviewed for consistency with our corporate objectives and compliance policies. Applicants outside of the U.S. must qualify as a charitable organization within the country where they reside.

This interactive portal allows you to: 1) provide necessary information so ADCT may appropriately evaluate your request, and 2) track the status of your request.

If your request does not fall under this category, we also have portals to evaluate other funding types. See links below:

Sponsorships/Memberships/Non-CME Grants
ADC Therapeutics’ interactive portal accepts unsolicited requests for sponsorships, corporate memberships, and non-CME grants that are aligned with ADCT’s mission, vision, and corporate objectives, and are consistent with our compliance policies.

This interactive portal allows you to: 1) provide necessary information so ADCT may appropriately evaluate your request, and 2) track the status of your request.

If your request does not fall under one of the mentioned categories, one of our other portals may fit your funding request. See links below:

Our History

2011
ADC Therapeutics founded as a spin-off from Spirogen Ltd. which was founded in 2000 and was an early innovator in PBD-based ADC research
2015
ADC Therapeutics cofounder Chris Martin appointed CEO
2016
First patient enrolled in phase 1 clinical trial of lead investigational compound loncastuximab tesirine-lpyl, targeting CD19 in positive B-cell non-Hodgkin lymphoma
2019
First patient enrolled in phase 2 clinical trial of investigational compound camidanlumab tesirine, targeting CD25 in relapsed or refractory Hodgkin lymphoma
2020
Ron Squarer, former CEO of Array BioPharma, Inc. appointed Chairman of the Board
$267-million IPO with the NYSE ticker “ADCT”
Announced pivotal phase 2 clinical trial of CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
Biologics license application (BLA) submission for CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
Biologics license application (BLA) acceptance with priority review for CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
2021
CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl receives FDA approval
2022
Industry veteran Ameet Mallik joins as CEO
2022
  • May
    Industry veteran Ameet Mallik joins as CEO
2021
  • April
    CD19-targeted, lead investigational compound
    loncastuximab tesirine-lpyl receives FDA approval
2020
  • November
    Biologics license application (BLA) acceptance with
    priority review for CD19-targeted, lead investigational
    compound loncastuximab tesirine-lpyl
  • September
    Biologics license application (BLA) submission for
    CD19-targeted, lead investigational compound
    loncastuximab tesirine-lpyl
  • June
    Announced pivotal phase 2 clinical trial of
    CD19-targeted, lead investigational compound
    loncastuximab tesirine-lpyl
  • May
    $267-million IPO with the NYSE ticker “ADCT”
  • March
    Ron Squarer, former CEO of Array BioPharma, Inc.
    appointed Chairman of the Board
2019
  • October
    First patient enrolled in phase 2 clinical trial of
    investigational compound camidanlumab tesirine,
    targeting CD25 in relapsed or refractory Hodgkin
    lymphoma
2016
  • March
    First patient enrolled in phase 1 clinical trial of lead
    investigational compound loncastuximab tesirine-lpyl,
    targeting CD19 in positive B-cell non-Hodgkin lymphoma
2015
  • June
    ADC Therapeutics cofounder Chris Martin appointed CEO
2011
  • June
    ADC Therapeutics founded as a spin-off from Spirogen
    Ltd. which was founded in 2000 and was an early
    innovator in PBD-based ADC research

ADC, antibody-drug conjugate; PBD, pyrrolobenzodiazepine.